BAXTER WILL NOT REPLACE PRESIDENT TOBIN FOLLOWING DEC. 23 RESIGNATION
BAXTER WILL NOT REPLACE PRESIDENT TOBIN FOLLOWING DEC. 23 RESIGNATION; his duties as chief operating officer are being reallocated to the three remaining members of Baxter's Office of the Chief Executive: Chairman/CEO Vernon Loucks, Exec VP-Hospital Business Lester Knight, and Exec VP-Global Business Tony White. James Tobin, 49, resigned as president, chief operating officer and board member "effective immediately."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth